We are live on ! Find out more
HRTX icon

Heron Therapeutics

141 hedge funds and large institutions have $122M invested in Heron Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 41 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,544% more call options, than puts

Call options by funds: $1.38M | Put options by funds: $16K

6% more capital invested

Capital invested by funds: $115M → $122M (+$7.21M)

1.54% more ownership

Funds ownership: 82.56%84.11% (+1.5%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

7% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 41

5% less funds holding

Funds holding: 149141 (-8)

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

Holders
141
Holders Change
-8
Holders Change %
-5.37%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
38
Reduced
41
Closed
19
Calls
$1.38M
Puts
$16K
Net Calls
+$1.37M
Net Calls Change
+$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
NAM
26
Nexpoint Asset Management
Texas
$514K
CM
27
CM Management
Florida
$464K -$71.2K -50,000 -10%
Morgan Stanley
28
Morgan Stanley
New York
$449K +$82.9K +58,237 +15%
SAM
29
Simplify Asset Management
Nevada
$445K +$213K +150,000 +53%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$364K +$27.5K +19,345 +6%
Los Angeles Capital Management
31
Los Angeles Capital Management
California
$353K +$5.2K +3,653 +1%
JAMONY
32
Jacob Asset Management of New York
California
$337K +$71.8K +50,435 +18%
ZDA
33
Zweig-DiMenna Associates
New York
$330K
Commonwealth Equity Services
34
Commonwealth Equity Services
Massachusetts
$324K +$23.4K +16,467 +6%
Renaissance Technologies
35
Renaissance Technologies
New York
$300K -$1.09M -767,800 -72%
KBC Group
36
KBC Group
Belgium
$298K
Fidelity Investments
37
Fidelity Investments
Massachusetts
$289K +$6.08K +4,272 +2%
Ameriprise
38
Ameriprise
Minnesota
$286K -$13.7K -9,633 -3%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$253K -$148K -103,687 -30%
MOACM
40
Mutual of America Capital Management
New York
$234K +$8.02K +5,637 +3%
AllianceBernstein
41
AllianceBernstein
Tennessee
$199K
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$189K -$253K -177,542 -49%
GCM
43
Graham Capital Management
Connecticut
$151K -$31.7K -22,276 -13%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$139K -$3.15K -2,216 -2%
WMSA
45
Weiss Multi-Strategy Advisers
New York
$132K -$21.5K -15,133 -11%
AQR Capital Management
46
AQR Capital Management
Connecticut
$126K -$35.8K -25,184 -17%
SFI
47
Susquehanna Fundamental Investments
Pennsylvania
$120K -$156K -109,539 -48%
RB
48
Richmond Brothers
Michigan
$106K +$86.3K +60,604 +143%
Bank of America
49
Bank of America
North Carolina
$94.5K +$44.4K +31,195 +51%
N
50
Nuveen
North Carolina
$94.5K

HRTX Hedge Fund Activity: Q3 2023 in Review

141 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2023, worth a combined $122M — up 6.3% from $115M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of HRTX and 14 opened new positions — a net loss of 5 holders — while 41 trimmed existing stakes and 38 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $21.3M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $1.5M sold.

  • 141 institutional investors held Heron Therapeutics (HRTX) as of Q3 2023, down from 149 in Q2 2023.
  • Funds reported $122M of Heron Therapeutics stock for Q3 2023, up 6.3% quarter-over-quarter.
  • 14 funds opened new Heron Therapeutics positions in Q3 2023 and 19 closed out, a net change of -5 holders.
  • The largest Heron Therapeutics buyer in Q3 2023 was Rubric Capital Management (New York), an estimated $21.3M added.
  • The largest Heron Therapeutics seller in Q3 2023 was Jefferies Financial Group, an estimated $1.5M sold.

Based on aggregated 13F filings for Q3 2023.